The concern of generic challenges has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, sparking questions about the prospects of related medicinal ventures. While initial years saw significant profits, the patent end has allowed the door for less expensive substitutes, possibly lowering earnings and creating a genuine danger